Abstract: Compositions and methods for the isolation of protein-nucleic acid complexes and microvesicles (collectively referred to as “bioparticles”) released by mammalian cells into body fluids or cell culture media are provided. Isolated bioparticles of the invention contain biological molecules that are useful as diagnostic/prognostic biomarkers or for identification of therapeutic targets (e.g., disease or disorder-associated miRNAs). The isolation of biological molecules as described herein results in purification and concentration of the molecules. Methods for producing bio fluids that are free of detectable bioparticles, that are largely depleted of bioparticles, or that possess a reduced concentration of bioparticles compared to a bio fluid starting material (collectively termed “bioparticle-depleted”) are also provided. Isolation of bioparticle-depleted biofluid is useful, e.g.
Type:
Grant
Filed:
August 5, 2015
Date of Patent:
June 2, 2020
Assignee:
YMIR GENOMICS, LLC
Inventors:
Patrick Shannon Pendergrast, Robert Scott Pendergrast, John Stephen Pendergrast, Anna Irmina Markowska
Abstract: Compositions and methods for the application of non-toxic bioparticle (e.g., extracellular vesicle (EV)) absorbing materials (e.g., non-toxic exosome reducing materials) for prophylactic, therapeutic, validation and/or experimental purposes are provided.
Type:
Application
Filed:
September 8, 2017
Publication date:
August 22, 2019
Applicant:
YMIR GENOMICS LLC
Inventors:
Patrick Shannon Pendergrast, Robert Scott Pendergrast, John Stephen Pendergrast, Anna Irmina Markowska
Abstract: Compositions and methods for the isolation of protein-nucleic acid complexes, extracellular vesicle (EV) (e.g., microvesicles) and free nucleic acids (collectively referred to as “bioparticles”) released by mammalian cells into body fluids or cell culture media are provided. Isolated bioparticles of the current disclosure contain biomolecules that are useful as diagnostic/prognostic biomarkers or for identification of therapeutic targets (e.g., disease or disorder-associated miRNAs, circulating tumor DNA). Isolation of biomolecules results in purification and concentration. Methods for producing biofluids without detectable bioparticles, largely depleted of bioparticles, and/or possessing a reduced concentration of bioparticles compared to a biofluid starting material (collectively termed “bioparticle-depleted”) are provided. Bioparticle-depleted biofluid is useful, e.g.
Type:
Application
Filed:
February 10, 2017
Publication date:
February 7, 2019
Applicant:
YMIR GENOMICS LLC
Inventors:
Patrick Shannon Pendergrast, Robert Scott Pendergrast, John Stephen Pendergrast, Anna Irmina Markowska